U.S. Markets open in 15 mins

AbbVie does not expect to divest new psoriasis drug

July 26 (Reuters) - AbbVie Inc said on Friday it does not expect the Federal Trade Commission would require divestiture of its recently approved psoriasis drug Skyrizi in connection with the company's $63 billion pending deal to buy Allergan Plc.

The company hopes Skyrizi will help it retain share in the psoriasis treatment market, as sales of its top-selling drug Humira face pressure from competition in Europe and could come under pressure in the United States starting 2023.

AbbVie expects Skyrizi sales of about $250 million in 2019, executives said on a conference call. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)